| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5642436 | Oral Oncology | 2017 | 7 Pages |
Abstract
Nivolumab is preferred to single-agent cetuximab but requires a willingness-to-pay of at least $150,000/QALY to be considered cost-effective when compared to docetaxel or methotrexate. Selection by PD-L1 does not markedly improve the cost-effectiveness of nivolumab. This informs patient selection and clinical care-path development.
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Matthew C. Ward, Chirag Shah, David J. Adelstein, Jessica L. Geiger, Jacob A. Miller, Shlomo A. Koyfman, Mendel E. Singer,